Presentations

Presentation: Isaralgagene civaparvovec (ST-920) shows positive mean annualized eGFR slope in adults with Fabry disease: Topline results from the registrational Phase 1/2 STAAR gene therapy study and long-term follow-up study
February 3rd, 2026
Presentation: Isaralgagene civaparvovec (ST-920) shows stable cardiac function over one year in patients with Fabry disease: Results from the registrational Phase 1/2 STAAR gene therapy study
February 3rd, 2026
Presentation: Isaralgagene civaparvovec (ST-920) gene therapy for adults with Fabry disease: Pharmacology and immunogenicity outcomes from the Phase 1/2 STAAR study and ongoing long-term follow-up
February 3rd, 2026
Presentation: A combined fertility, embryofetal development, AAV integration and germline transmission risk study in mice with ST-920 (isaralgagene civaparvovec) for Fabry disease
February 3rd, 2026
Poster: ST-506 mediates brainwide lowering of prion protein in nonhuman primates via a conserved blood-brain-barrier crossing mechanism, as a potential one-time treatment for prion disease
November 13th, 2025
Poster: Preclinical Development of ST-503: an Investigational Adeno-associated Viral Vector Delivered Zinc Finger Repressor Novel Epigenetic Therapy for Idiopathic Small Fiber Neuropathy
September 10th, 2025
Poster: Isaralgagene Civaparvovec (ST-920) Shows Positive Mean Annualized eGFR Slope in Adults with Fabry Disease: Updated Results from the Registrational Phase 1/2 STAAR Gene Therapy Study
September 6th, 2025
Presentation: Isaralgagene Civaparvovec (ST-920) Gene Therapy in Adults with Fabry Disease: Updated Results from an Ongoing Phase 1/2 Study (STAAR)
February 10th, 2025
Poster: Isaralgagene Civaparvovec (ST-920) Gene Therapy in Adults with Fabry Disease: Updated Results from an Ongoing Phase 1/2 Study (STAAR)
February 10th, 2025
Efficacy and Safety of Giroctocogene Fitelparvovec in Adults With Moderately Severe to Severe Hemophilia A: Primary Analysis Results From the Phase 3 AFFINE Gene Therapy Trial
December 10th, 2024